mCRC Clinical Studies in First Line

Three large RCTs, SIRFLOX, FOXFIRE and FOXFIRE Global, investigated the first-line use of SIR-Spheres® Y-90 resin microspheres in addition to chemotherapy in metastatic colorectal cancer (mCRC). Key endpoints from the SIRFLOX study were reported at the American Society of Clinical Oncology (ASCO) 2015 Annual Meeting and published in the Journal of Clinical Oncology in 2016. Overall Survival (OS) data from the three studies were presented as the FOXFIRE Combined Analysis, at the 2017 ASCO meeting. Subsequently a clinically relevant post hoc analysis addressing efficacy in patients with a right-sided primary tumour was presented at European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer (WCGIC), 2017.

REsect, a retrospective, blinded evaluation of CT scans from the SIRFLOX study patient cohort on eligibility for hepatic resection, was presented at the 12th International Congress of the European-African Hepato-Pancreato-Biliary Association (E-AHPBA), May 2017.

SIR-Spheres Y-90 resin microspheres have been extensively investigated in the treatment of liver metastases from colorectal cancer. Numerous studies, including several randomised controlled trials, have been published on the combination of SIR-Spheres Y-90 resin microspheres with chemotherapy in first and subsequent lines as well as a monotherapy for mCRC. View summary of published data for SIR-Spheres Y-90 resin microspheres in the treatment of mCRC

Now leaving

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.



You are now leaving your current region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.



This content is intended for healthcare professionals only

By clicking "Yes" you are confirming that you are a healthcare professional. If you are not a healthcare professional, then please click "Go to Homepage" which will direct you to the Sirtex homepage.

Yes Go to Homepage